For a 7‑year‑old child with PANS/PANDAS whose motor or vocal tics and OCD improve with anti‑inflammatory therapy but flare when the medication is stopped or during viral upper‑respiratory infections, what is the role of intravenous immunoglobulin (IVIG) and when should it be initiated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What Does IVIG Do in PANS/PANDAS?

IVIG modulates inflammation by reducing pro-inflammatory immune cells and may improve neuropsychiatric symptoms in PANS/PANDAS, but the evidence remains mixed and it should be reserved for moderate-to-severe cases that have failed standard anti-inflammatory therapy.

Mechanism of Action

IVIG functions as an immunomodulatory agent through multiple pathways 1:

  • Reduces pro-inflammatory monocytes and dendritic cells in the circulation, which correlates with improvement in obsessive-compulsive and tic symptoms 2
  • Modulates autoimmune responses by interfering with cross-reactive antibodies that target brain nuclei through molecular mimicry following streptococcal or other infections 3
  • Suppresses neuroinflammation in basal ganglia and other brain regions implicated in PANS/PANDAS pathophysiology 3
  • Provides anti-inflammatory effects through both IgG variable and constant fragment mechanisms 1

Evidence for Efficacy in PANS/PANDAS

Mixed Trial Results

The evidence base shows conflicting outcomes:

  • The 2016 randomized controlled trial failed to demonstrate superiority over placebo in the double-blind phase, with only 35% response rate in IVIG group versus 22% in placebo group (not statistically significant) 4
  • However, open-label follow-up showed 55% improvement at 12 weeks and 62% at 24 weeks, suggesting delayed or cumulative effects 4
  • A 2022 open-label trial of 10 children showed marked improvement, with 9 of 10 children achieving >30% reduction in PANS scale scores after three monthly treatments 5
  • A 2024 study demonstrated statistically significant improvements in CY-BOCS, YGTSS tic scales, and parent PANS ratings (all p<0.001) following six IVIG infusions 2

Biological Correlates

  • Pro-inflammatory monocyte reduction correlates with clinical improvement, both as a proportion of CD14+ cells and in absolute numbers 2
  • Improvements occur across multiple domains: obsessive-compulsive symptoms, tics, behavioral regression, and school attendance 5

When to Initiate IVIG

IVIG should be considered for children with moderate-to-severe PANS/PANDAS who meet ALL of the following criteria:

  1. Documented acute-onset neuropsychiatric symptoms including OCD or eating restriction plus at least two co-occurring symptoms (tics, behavioral regression, anxiety, etc.) 2, 3

  2. Inadequate response to first-line anti-inflammatory therapy (NSAIDs, corticosteroids, or antibiotics if streptococcal trigger identified) 3

  3. Significant functional impairment affecting school attendance, family functioning, or quality of life 5

  4. Evidence of inflammatory flares temporally associated with viral upper respiratory infections or other infectious triggers 2, 3

  5. Moderate-to-severe OCD symptoms as measured by standardized scales (CY-BOCS score typically >16) 4, 5

Dosing Protocol

Based on the strongest evidence from recent trials:

  • Initial course: 1-2 g/kg divided over 1-2 consecutive days 4, 5
  • Repeat monthly for 3-6 months to achieve sustained benefit 2, 5
  • Assess response at 4 weeks after each infusion using standardized measures (CY-BOCS, PANS scale, CGI-I) 2, 4

The 2022 trial used 2 g/kg monthly for three months with good results 5, while the 2024 study used six infusions every 3 weeks 2. The monthly dosing schedule appears more practical and equally effective.

Important Caveats and Pitfalls

Side Effects

  • Moderate-to-severe transient side effects occur in approximately 30% after first infusion but diminish substantially with subsequent treatments 5
  • Monitor for hemolytic anemia and volume overload, particularly in patients with cardiac dysfunction 6
  • Assess cardiac function and fluid status before infusion; slow infusion rate or divide over 2 days if abnormal 6

Clinical Pitfalls

  • Do not expect immediate response: Improvements may be delayed, with maximal benefit at 12-24 weeks 4
  • Single-dose trials underestimate efficacy: The failed RCT used only one course, while successful open-label studies used 3-6 monthly infusions 2, 4, 5
  • Placebo response is substantial (22% in RCT), so objective measurement with validated scales is essential 4
  • IVIG is NOT indicated for mild PANS/PANDAS or as first-line therapy 3, 4

Lack of Guideline Support

Critically, IVIG is not mentioned in major immunology or rheumatology guidelines for PANS/PANDAS 7. The evidence provided focuses on MIS-C (multisystem inflammatory syndrome in children related to COVID-19), which is a distinct entity [6-6]. PANS/PANDAS lacks the established guideline support that exists for conditions like Guillain-Barré syndrome, myasthenia gravis, or immune thrombocytopenia 7.

Practical Algorithm

For your 7-year-old patient with motor/vocal tics and OCD that flares with infections:

  1. Document baseline severity using CY-BOCS and YGTSS tic scales
  2. Optimize anti-inflammatory therapy (consider corticosteroid burst during acute flares)
  3. If symptoms remain moderate-to-severe despite 2-3 months of anti-inflammatory therapy, consider IVIG trial
  4. Administer 2 g/kg monthly for 3 months with pre-treatment cardiac assessment
  5. Reassess at 4 weeks after each infusion using standardized scales
  6. Define response as ≥30% reduction in CY-BOCS and "much improved" on CGI-I 4
  7. If no response after 3 monthly treatments, discontinue and consider alternative immunomodulatory approaches (high-dose corticosteroids, rituximab) 3

The decision to use IVIG should involve subspecialty consultation with pediatric rheumatology, immunology, or psychiatry given the lack of established guidelines and mixed evidence 7, 3.

References

1
Research

Mechanisms of action of intravenous immunoglobulins.

Expert review of clinical immunology, 2010

7
Guideline

IVIG Use in Specific Clinical Contexts

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Is Intravenous Immunoglobulin (IVIG) therapy medically necessary for a 14-year-old female patient with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS), Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, and Obsessive-Compulsive Disorder (OCD) symptoms, who is currently taking Prozac (fluoxetine), Adderall (amphetamine and dextroamphetamine), and low-dose naltrexone?
In a 24-year-old female with a 4-year history of PANS receiving IVIG who presents with fatigue and brain fog, normal CBC and iron studies, and euthyroid thyroid function tests but intermittent elevations of anti‑thyroperoxidase and anti‑thyroglobulin antibodies, what follow‑up laboratory testing and management steps are recommended?
What symptoms can a 26-year-old experience if they had Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal (PANDAS) infections as a child that were not diagnosed or treated?
Could my 4-year-old's recent escalation of moody behavior, screaming, crying, and tantrums after a streptococcal (strep) infection be indicative of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS), given her sibling has been diagnosed with PANS/PANDAS?
What is the first line of treatment for managing a PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) patient flare?
What are the differential diagnoses for painful versus painless jaundice in a patient presenting with a palpable gallbladder (Courvoisier's sign)?
Is it appropriate to give ceftriaxone intravenous together with oral nitrofurantoin (Macrobid) at the same time?
What are the recommended dose, contraindications, adverse effects, monitoring parameters, and alternative treatments for Salagen (pilocarpine) in patients with symptomatic xerostomia from head‑and‑neck radiation or Sjögren’s syndrome?
In a patient with Hashimoto’s thyroiditis who has a goiter but normal thyroid‑stimulating hormone and free thyroxine levels, what is the appropriate next step in management?
What are the likely causes of arm pain after an intravenous hydration infusion and how should it be assessed and managed?
Are there any studies on Japanese knotweed for the treatment or prevention of tick‑borne infections such as Lyme disease, anaplasmosis, babesiosis, or ehrlichiosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.